|
Lebanon Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Lebanon Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Lebanon .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Lebanese pharmaceutical and healthcare industry.
Competitive intelligence, Lebanese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Lebanese market.
The Lebanon Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- 2013 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Lebanon Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Lebanese pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Lebanon to test other views – a key input for successful budgeting and strategic business planning in the Lebanese pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Lebanese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Lebanon .
- Exploit The Latest Competitive Lebanese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Lebanon .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- 2013 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Lebanon Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Political SWOT |
| Economic SWOT |
| Business Environment SWOT |
| Lebanon Pharmaceuticals And Healthcare Industry SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Lebanon – Market Summary |
| Regulatory Regime |
| Public Sector Procurement |
| Intellectual Property Regime |
| Table: USTR ‘Special 301' Report 2007 |
| IP Shortcomings |
| Parallel Imports |
| Counterfeit Drugs |
| Table: Losses Owing To Counterfeit Drugs In The Middle East, 2007 |
| Free Trade Agreements |
| Pricing and Reimbursement Issues |
| Table: Lebanon's Incremental Drug Margins (%) |
Chapter - Industry Developments |
| Epidemiology |
| HIV/AIDS Infections |
| Healthcare Sector |
| Hospital Sector |
| Healthcare Insurance |
| Healthcare Sector Reforms |
| Regional Developments |
| Pharmaceuticals Sector |
| Recent Pharmaceutical Industry Developments |
| Research and Development |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecasts |
| Table: Lebanon – Drug Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Industry |
| Table: Lebanon – Health Expenditure, 2003-2013 |
| Key Growth Factors – Macroeconomic |
| TABLE: LEBANON – ECONOMIC ACTIVITY |
| Prescription Market Forecast |
| Table: Lebanon – Prescription Market Indicators, 2005-2013 (LBPmn unless otherwise indicated) |
| OTC Market Forecast |
| Table: Lebanon – OTC Market Indicators, 2005-2013 (LBPmn unless otherwise indicated) |
| Patented Drug Market Forecast |
| Table: Lebanon – Patented Market Indicators, 2003-2013 |
| Generic Drug Market Forecast |
| Table: Lebanon – Generics Market Indicators, 2003-2013 |
| Pharmaceutical Export/Import Market Forecasts |
| Table: Lebanon - Pharmaceutical Export/Import Indicators, 2003-2013 (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Lebanon – Other Healthcare Data, 2003-2013 |
| Key Risks to BMI Forecasts |
Chapter - Competitive Landscape |
| Company Profiles |
| Multinational Companies |
| Pfizer |
| Novartis |
| Merck & Co |
| Johnson & Johnson |
| Sanofi-Aventis |
| Abbott Laboratories |
| Indigenous Companies |
| Chalhoub Pharmaceuticals (CHAPHA) |
| Alfa Laboratories |
| Algorithm |
| Codipha |
Chapter - Country Snapshot: Lebanon Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Lebanon Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Lebanon’s pharmaceutical market was worth US$500mn in 2008, and is expected to grow to be worth US$517mn in 2009. It is further expected to reach US$605mn by 2013, representing a CAGR of 3.95%. Before the country's civil war, which ended in 1990, Lebanon had one of the strongest pharmaceutical industries in the region. However, neighbouring markets have built up their facilities to the extent that they have now overtaken the country’s own, and further conflicts in 2006 and 2007 have deepened this discrepancy.
In BMI’s updated Business Environment Ratings for Q209, Lebanon has fallen in the matrix ranking 17 key markets in the Middle East and Africa (MEA) region once more. It now occupies 14h position, compared to 13th at the beginning of the year. The low rank achieved by the country is a result of a poor regulatory and intellectual property regime, a small population size, political volatility and limited healthcare finances.
Foreign drug companies dominate the market in value terms, although none operate local manufacturing facilities, opting instead to import medicines via regional or local distribution offices. European and North American companies are marketplace leaders, although no single company holds a commanding share. The dominance of foreign firms can prove an advantage, as it provides local producers with easy access to technology through co-operation agreements. However, the unwillingness of foreign companies to invest in country as a result of existing risks limits market growth, despite Lebanon’s onetime position as of the most attractive countries for investment in the Middle East.
The Lebanese pharmaceutical market will remain almost entirely reliant on imports, accounting for more than 90% of spending, with more than 50 pharmaceutical importers active in the country. However, local Lebanese industrialists are taking advantage of generous government subsidies, low costs and accessible capital to expend abroad. Domestic production will remain limited, owing to high costs, uncertain quality and an unsettled political situation, despite the obvious potential for meeting the needs of a rapidly growing population.
It is estimated that up to 40% of the Lebanese population do not have any type of insurance coverage, which has also negatively impacted on patients’ access to medicines. However, in October 2008, the Lebanese Ministry of Public Health announced that it was to launch a project to make health insurance compulsory for all Lebanese citizens. This should result in a more efficient healthcare system and boost pharmaceutical expenditure.
|
Lebanon Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |